Skip to main content

Metabolic Disorders

1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD2693Phase 11 trial
Active Trials
NCT04142424Completed73Est. Nov 2021
Parexel
ParexelMA - Boston
1 program
AZD2693PHASE_1
Fate Therapeutics
Fate TherapeuticsSAN DIEGO, CA
1 program
ProHema-CB TransplantPHASE_11 trial
Active Trials
NCT02354443Terminated1Est. Feb 2017
Regeneron
RegeneronTARRYTOWN, NY
1 program
REGN1500PHASE_11 trial
Active Trials
NCT02107872Completed55Est. Sep 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaAZD2693
Fate TherapeuticsProHema-CB Transplant
RegeneronREGN1500

Clinical Trials (3)

Total enrollment: 129 patients across 3 trials

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

Start: Oct 2019Est. completion: Nov 202173 patients
Phase 1Completed
NCT02354443Fate TherapeuticsProHema-CB Transplant

A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders

Start: Jun 2015Est. completion: Feb 20171 patients
Phase 1Terminated

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Start: Apr 2014Est. completion: Sep 201555 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.